Head and Neck Cancer Clinical Trials in Nashville, Tennessee
11 studies are recruiting for head and neck cancer in Nashville, Tennessee right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.
Search these by distance from you
Studies now recruiting
-
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma [cutaneous/acral], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric can…
- Stage
- Phase 2
- Ages
- 18 and older
- Site
- SCRI Oncology Partners, Nashville, Tennessee
- Locations
- 90 in total
- Run by
- Daiichi Sankyo
-
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…
- Stage
- Phase 1
- Ages
- 12 and older
- Site
- Sarah Cannon Research Institute, Nashville, Tennessee
- Locations
- 77 in total
- Run by
- PMV Pharmaceuticals, Inc
-
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
A phase 1 study to determine the safety, tolerability, PK, PD, and preliminary anti-tumor activity of ascending doses of EPI-326 administered to patients with locally advanced or metastatic HNSCC and to patients with any documented EGFR-mutant locally advanced or metastatic NSCLC.
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Sarah Cannon and HCA Research Institute, Nashville, Tennessee
- Locations
- 6 in total
- Run by
- EpiBiologics
-
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'. ADCs…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Sarah Cannon Research Institute - Pharmacy, Nashville, Tennessee
- Locations
- 31 in total
- Run by
- Pfizer
-
DESTINY-PANTUMOUR04
This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world…
- Stage
- Not phased
- Ages
- 18 to 130
- Site
- Research Site, Nashville, Tennessee
- Locations
- 18 in total
- Run by
- AstraZeneca
-
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizuma…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Vanderbilt University School of Medicine, Nashville, Tennessee
- Locations
- 42 in total
- Run by
- Inhibrx Biosciences, Inc
-
Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema
The U.S. Food and Drug Administration approved photobiomodulation therapy (PBMT) as a treatment for breast cancer-related arm lymphedema (BCRL) in 2006. The investigators conducted two pilot clinical trials. Results demonstrated the feasibility, acceptability, and preliminary efficacy of PBMT for t…
- Stage
- Not phased
- Ages
- 18 and older
- Site
- Vanderbilt University Medical Center, Nashville, Tennessee
- Locations
- 2 in total
- Run by
- Abramson Cancer Center at Penn Medicine
-
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Sarah Cannon Research Institute, Nashville, Tennessee
- Locations
- 6 in total
- Run by
- ModeX Therapeutics, An OPKO Health Company
-
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gast…
- Stage
- Not phased
- Ages
- 40 and older
- Site
- Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
- Locations
- 17 in total
- Run by
- Adela, Inc
-
Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants
RATIONALE: Collecting and storing samples of tissue, saliva, and blood from patients with cancer and from healthy participants to study in the laboratory may help the study of cancer in the future. PURPOSE: This research study is collecting and storing tissue samples from patients with head and nec…
- Stage
- Not phased
- Ages
- 18 and older
- Site
- Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee
- Locations
- 4 in total
- Run by
- Vanderbilt University Medical Center
-
Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer
This is a study to establish a safe and feasible dose for prophylactic use of a combination of gabapentin and ketamine in head and neck cancer patients undergoing chemoradiation.
- Stage
- Phase 1
- Ages
- 21 and older
- Site
- Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
- Run by
- Natalie Lockney
How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.
What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.
Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.